Αποτελέσματα αναζήτησης - Nikolaj Frost

  • Εμφανίζονται 1 - 10 Αποτελέσματα από 10
Περιορισμός αποτελεσμάτων
  1. 1
    Regulation of Peroxisome Proliferator–Activated Receptor γ Activity by Losartan Metabolites

    Regulation of Peroxisome Proliferator–Activated Receptor γ Activity by Losartan Metabolites από Michael Schupp, Lucas D. Lee, Nikolaj Frost, Sumaira Umbreen, Boris Schmidt, Thomas Unger, Ulrich Kintscher

    Έκδοση 2005
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Liver-Specific Peroxisome Proliferator–Activated Receptor α Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan

    Liver-Specific Peroxisome Proliferator–Activated Receptor α Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan από Markus Clemenz, Nikolaj Frost, Michael Schupp, Sandrine Caron, Anna Foryst‐Ludwig, Christian Böhm, Martin Hartge, Ronald Gust, Bart Staels, Thomas Unger, Ulrich Kintscher

    Έκδοση 2008
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    Metabolic Actions of Estrogen Receptor Beta (ERβ) are Mediated by a Negative Cross-Talk with PPARγ

    Metabolic Actions of Estrogen Receptor Beta (ERβ) are Mediated by a Negative Cross-Talk with PPARγ από Anna Foryst‐Ludwig, Markus Clemenz, Stephan Hohmann, Martin Hartge, C Sprang, Nikolaj Frost, Maxim Krikov, Sanjay Bhanot, Rodrigo P. A. Barros, Andrea Morani, Jan-Ακε Gustafsson, Thomas Unger, Ulrich Kintscher

    Έκδοση 2008
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

    KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma από Nikolaj Frost, Jens Kollmeier, Claudia Vollbrecht, Christian Grah, Burkhard Matthes, Dennis Pultermann, Maximilian von Laffert, H Lüders, Elisabeth Olive, Matthias Raspe, Thomas Mairinger, Sebastian Ochsenreither, Torsten Blum, Michael Hummel, Norbert Suttorp, Martin Witzenrath, Christian Grohé

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer

    DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer από Philipp Jurmeister, Anne Schöler, Alexander Arnold, Frederick Klauschen, Dido Lenze, Michael Hummel, Leonille Schweizer, Hendrik Bläker, Berit M. Pfitzner, Soulafa Mamlouk, Christine Sers, Carsten Denkert, Damian Stichel, Nikolaj Frost, David Horst, Maximilian von Laffert, David Capper

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

    Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program από Nikolaj Frost, Petros Christopoulos, Diego Kauffmann‐Guerrero, Jan A. Stratmann, Richard Riedel, Monica Schaefer, Jürgen Alt, S Gütz, Daniel C. Christoph, Eckart Laack, Martin Faehling, Richard Fischer, Klaus Fenchel, Sebastian P. Haen, Lukas C. Heukamp, Christian Schulz, Frank Griesinger

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

    Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer από Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, В. В. Бредер, Dariusz M. Kowalski, Theodore Pollock, E. Levchenko, Noemı́ Reguart, Alex Martínez‐Martí, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations από Miriam Blasi, Jonas Kuon, H Lüders, Daniel Misch, Diego Kauffmann‐Guerrero, Moritz Hilbrandt, Daniel Kazdal, Roger-Fei Falkenstern-Ge, Björn Hackanson, Sebastian Dintner, Martin Faehling, Martina Kirchner, Anna‐Lena Volckmar, Hans‐Georg Kopp, Michael Allgäuer, Christian Grohé, Amanda Tufman, Martin Reck, Nikolaj Frost, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos

    Έκδοση 2024
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany από Jan A. Stratmann, Friederike C. Althoff, Paula Doebel, Jacqueline Rauh, Arne Trummer, A Hünerlitürkoglu, Nikolaj Frost, Hüsameddin Yildirim, Petros Christopoulos, Oswald Burkhard, Christian Meyer zum Büschenfelde, Aaron Becker von Rose, Jürgen Alt, Sven Philip Aries, Maximilian Webendörfer, Stefan Kaldune, Mark Uhlenbruch, Guergana Tritchkova, Cornelius F. Waller, Achim Rittmeyer, Petra Hoffknecht, Jan Braess, Hans‐Georg Kopp, Christian Grohé, Monica Schäfer, Christian Schumann, Frank Griesinger, Jonas Kuon, Martin Sebastian, Niels Reinmuth

    Έκδοση 2024
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  10. 10
    Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

    Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Netwo... από Philip Bischoff, Martin Reck, Tobias R. Overbeck, Petros Christopoulos, Achim Rittmeyer, H Lüders, Jens Kollmeier, Jonas Kulhavy, Marcel Kemper, Niels Reinmuth, J Roper, Melanie Janning, Linna Sommer, Lukas Aguinarte, Myriam Koch, Marcel Wiesweg, Claas Wesseler, Cornelius F. Waller, Diego Kauffmann‐Guerrero, Albrecht Stenzinger, Susann Stephan-Falkenau, Marcel Trautmann, Silke Laßmann, Markus Tiemann, Frederick Klauschen, Martin Sebastian, Frank Griesinger, Jürgen Wolf, Sonja Loges, Nikolaj Frost, Moritz Hilbrandt, Juliane Süptitz, Christian Grah, Janna-Lisa Velthaus, Hans‐Georg Kopp, Bernd Schmidt, Susanne Horter, Stefanie Keymel, Enver Aydilek, Guergana Tritchkova, Matthias Raspe, Dražen Papić, Stefan Florian, David Horst, Peter J. Wild, Michael Thomas, Christian Grohé, Annalen Bleckmann, Martin Wermke, Horst-Dieter Hummel, Jan A. Stratmann, Wolfgang Schütte

    Έκδοση 2023
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: